Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes

INTRODUCTION: Recently, the sodium-glucose cotransporter2 (SGLT2) inhibitor empagliflozin has been shown to lower cardiovascular risk among diabetic patients. It is intriguing that some SGLT2 inhibitors have been found to increase low-density lipoprotein (LDL) cholesterol levels, while the relevance...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamijo, Yuka, Ishii, Hideto, Yamamoto, Tomohiko, Kobayashi, Kunihisa, Asano, Hiroyuki, Miake, Shunji, Kanda, Eiichiro, Urata, Hidenori, Yoshida, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696845/
https://www.ncbi.nlm.nih.gov/pubmed/31452606
http://dx.doi.org/10.1177/1179551419866811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696845/
https://www.ncbi.nlm.nih.gov/pubmed/31452606
http://dx.doi.org/10.1177/1179551419866811

Ejemplares similares